Zenas BioPharma, Inc. (ZBIO)
29.43
+1.17
(+4.14%)
USD |
NASDAQ |
Nov 09, 14:28
Zenas BioPharma PS Ratio : 154.76 for Nov. 9, 2026
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| November 06, 2026 | 148.61 |
| November 05, 2026 | 136.36 |
| November 04, 2026 | 149.66 |
| November 03, 2026 | 149.24 |
| November 02, 2026 | 145.24 |
| October 30, 2026 | 149.29 |
| October 29, 2026 | 151.24 |
| October 28, 2026 | 151.29 |
| October 27, 2026 | 143.56 |
| October 26, 2026 | 143.24 |
| October 23, 2026 | 141.30 |
| October 22, 2026 | 148.45 |
| October 21, 2026 | 147.66 |
| October 20, 2026 | 148.19 |
| October 19, 2026 | 140.46 |
| October 16, 2026 | 130.62 |
| October 15, 2026 | 133.57 |
| October 14, 2026 | 130.73 |
| October 13, 2026 | 132.31 |
| October 12, 2026 | 138.83 |
| October 09, 2026 | 143.35 |
| October 08, 2026 | 137.99 |
| October 07, 2026 | 148.19 |
| October 06, 2026 | 141.67 |
| October 05, 2026 | 146.35 |
| Date | Value |
|---|---|
| October 02, 2026 | 148.79 |
| October 01, 2026 | 146.93 |
| September 30, 2026 | 141.82 |
| September 29, 2026 | 1387.44 |
| September 28, 2026 | 1428.40 |
| September 25, 2026 | 1397.29 |
| September 24, 2026 | 1425.81 |
| September 23, 2026 | 1536.24 |
| September 22, 2026 | 1713.56 |
| September 21, 2026 | 1687.64 |
| September 18, 2026 | 1633.20 |
| September 17, 2026 | 1657.57 |
| September 16, 2026 | 1675.71 |
| September 15, 2026 | 1655.49 |
| September 14, 2026 | 1654.46 |
| September 11, 2026 | 1613.50 |
| September 10, 2026 | 1612.46 |
| September 09, 2026 | 1674.16 |
| September 08, 2026 | 1713.56 |
| September 04, 2026 | 1704.75 |
| September 03, 2026 | 1706.82 |
| September 02, 2026 | 1717.71 |
| September 01, 2026 | 1658.09 |
| August 31, 2026 | 1675.71 |
| August 28, 2026 | 1621.27 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.792 |
| Alnylam Pharmaceuticals, Inc. | 4.304 |
| Anika Therapeutics, Inc. | 1.633 |
| Savara, Inc. | -- |
| Vericel Corp. | 9.346 |
PS Ratio Related Metrics
| PEG Ratio | -0.0241 |
| Price to Book Value | 9.398 |
| Price | 29.43 |
| Earnings Yield | -34.12% |
| Market Cap | 1.864B |
| PEGY Ratio | -0.0241 |